Inspire Medical Systems, Inc. $INSP Shares Acquired by Royal Bank of Canada

Royal Bank of Canada raised its position in Inspire Medical Systems, Inc. (NYSE:INSP) by 2,203.1% in the first quarter, Holdings Channel reports. The fund owned 252,971 shares of the company’s stock after buying an additional 241,987 shares during the period. Royal Bank of Canada’s holdings in Inspire Medical Systems were worth $13,049,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in INSP. CWM LLC raised its holdings in shares of Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after purchasing an additional 242 shares in the last quarter. Havemeyer Place LP acquired a new position in shares of Inspire Medical Systems during the fourth quarter worth $39,000. V Square Quantitative Management LLC acquired a new position in shares of Inspire Medical Systems during the fourth quarter worth $40,000. Smartleaf Asset Management LLC increased its holdings in Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after buying an additional 205 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in Inspire Medical Systems by 21,266.7% in the third quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock valued at $48,000 after buying an additional 638 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Stock Performance

Shares of Inspire Medical Systems stock opened at $60.12 on Friday. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03. The company has a market capitalization of $1.74 billion, a P/E ratio of 13.01, a PEG ratio of 4.48 and a beta of 0.70. The company’s fifty day moving average is $47.64 and its two-hundred day moving average is $54.51.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business had revenue of $200.58 million during the quarter, compared to analysts’ expectations of $194.72 million. During the same period in the prior year, the company earned $0.45 earnings per share. The business’s revenue was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities analysts expect that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Summit Redstone set a $39.00 price target on Inspire Medical Systems in a report on Friday, May 22nd. Zacks Research upgraded Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price on the stock. in a research report on Friday, May 22nd. Weiss Ratings restated a “sell (d)” rating on shares of Inspire Medical Systems in a research note on Monday. Finally, UBS Group started coverage on Inspire Medical Systems in a report on Tuesday, July 28th. They issued a “sell” rating and a $39.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $68.00.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.